dbacp04349
General Description
Peptide name : Lytic
Source/Organism : Bovine lactoferrin (Lf-B)
Linear/Cyclic : Linear
Chirality : Mix
Sequence Information
Sequence : KLlLKlLkkLLKlLKKK
Peptide length: 17
C-terminal modification: Linear
N-terminal modification : Free
Non-natural peptide information: None
Activity Information
Assay type : WST-1 assay
Assay time : 24h
Activity : IC50 : 37.4 µMol/L
Cell line : KB
Cancer type : Oral cancer
Other activity : Not found
Physicochemical Properties
Amino acid composition bar chart :
Molecular mass : 2061.8121 Dalton
Aliphatic index : 1.376
Instability index : -30.541
Hydrophobicity (GRAVY) : 0.1765
Isoelectric point : 10.845
Charge (pH 7) : 7.7521
Aromaticity : 0
Molar extinction coefficient (cysteine, cystine): (0, 0)
Hydrophobic/hydrophilic ratio : 1
hydrophobic moment : -1.090
Missing amino acid : W,T,P,I,M,E,F,D,N,G,C,R,H,Q,S,Y,A,V
Most occurring amino acid : K
Most occurring amino acid frequency : 6
Least occurring amino acid : k
Least occurring amino acid frequency : 2
Structural Information
3D structure :
Secondary structure fraction (Helix, Turn, Sheet): (1, 0, 0.5)
SMILES Notation: CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
Secondary Structure :
| Method | Prediction |
|---|---|
| GOR | HHHHHHHHHHHHHHHHH |
| Chou-Fasman (CF) | HHHHHHHHHHHHHHCCC |
| Neural Network (NN) | HHHHHHHHHHHHHHHHC |
| Joint/Consensus | HHHHHHHHHHHHHHHHC |
Molecular Descriptors and ADMET Properties
Molecular Descriptors: Click here to download
ADMET Properties: Click here to download
Cross Referencing databases
Reference
1 : Yang L, et al. Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy. Mol Cancer Ther. 2012; 11:235-43. doi: 10.1158/1535-7163.MCT-11-0363
Literature
Paper title : Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy.
Doi : https://doi.org/10.1158/1535-7163.MCT-11-0363
Abstract : Interleukin-4 receptor α (IL-4Rα) chain is highly expressed on the surface of various human solid tumors. We designed a novel hybrid peptide termed IL-4Rα-lytic peptide that targets the IL-4Rα chain. The IL-4Rα-lytic peptide contains a target moiety to bind to IL-4Rα and a cellular toxic lytic peptide that selectively kills cancer cells. The anticancer activity of the IL-4Rα-lytic peptide was evaluated in vitro and in vivo. It was found that the IL-4Rα-lytic peptide has cytotoxic activity in cancer cell lines expressing IL-4Rα, determined by quantitative real-time PCR. The IC(50) ratios of the lytic peptide to the IL-4Rα-lytic peptide correlated well with the expression levels of IL-4Rα on cancer cells (r = 0.80). In addition, IL-4Rα-lytic peptide administered either intratumoraly or intravenously significantly inhibited tumor growth in xenograft model of human pancreatic cancer (BXPC-3) in mice. These results indicate that the IL-4Rα-lytic peptide generated in this study has a potent and selective anticancer potential against IL-4Rα-positive solid cancers.